Evidence mapPaperPMID 32630698Full record

ReviewInternational journal of molecular sciences2020

Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights.

Unai Galicia-Garcia, Shifa Jebari, Asier Larrea-Sebal, Kepa B Uribe, Haziq Siddiqi, Helena Ostolaza, Asier Benito-Vicente, César Martín

Open access · goldFull text readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 4 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 4 syntheses or guidelines pooled it, 145 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy.International journal of environmental research and public health · 2022
    Pooled it
  5. Trial
  6. Review
  7. Article
  8. Epigenetic regulation in a high-sugar environment (Review).International journal of molecular medicine · 2026
    Review
  9. Review
  10. Article
  11. Review
  12. Current perspectives on lipid management in diabetic kidney disease: Can fibrates offer advantages over statins for renal outcomes?Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Unai Galicia-GarciaFundación Biofisika Bizkaia, Barrio Sarriena s/n, 48940 Leioa, Spain.
Shifa JebariBiofisika Institute (UPV/EHU, CSIC), Barrio Sarriena s/n, 48940 Leioa, Spain.
Asier Larrea-SebalFundación Biofisika Bizkaia, Barrio Sarriena s/n, 48940 Leioa, Spain.
Kepa B UribeCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo de Miramon 182, 20014 Donostia San Sebastián, Spain.ORCID 0000-0002-4502-4853
Haziq SiddiqiHarvard Medical School, Harvard University, 25 Shattuck St, Boston, MA 02115, USA.
Helena OstolazaFundación Biofisika Bizkaia, Barrio Sarriena s/n, 48940 Leioa, Spain.
Asier Benito-VicenteFundación Biofisika Bizkaia, Barrio Sarriena s/n, 48940 Leioa, Spain.
César MartínFundación Biofisika Bizkaia, Barrio Sarriena s/n, 48940 Leioa, Spain.ORCID 0000-0002-4087-8729
Instituto Biofisika · ESCIC biomaGUNE · ESHarvard University · USUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statins are the gold-standard treatment for the prevention of primary and secondary cardiovascular disease, which is the leading cause of mortality worldwide. Despite the safety and relative tolerability of statins, observational studies, clinical trials and meta-analyses indicate an increased risk of developing new-onset type 2 diabetes mellitus (T2DM) after long-term statin treatment. It has been shown that statins can impair insulin sensitivity and secretion by pancreatic β-cells and increase insulin resistance in peripheral tissues. The mechanisms involved in these processes include, among others, impaired Ca

Indexed as

AdipocytesCardiovascular DiseasesDiabetes Mellitus, Type 2Glucose Transporter Type 4HumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperinsulinismInsulinInsulin ResistanceInsulin-Secreting CellsInsulin SecretionRisk FactorsGlucose Transporter Type 4Hydroxymethylglutaryl-CoA Reductase InhibitorsInsulinclinical trialinsulin resistancemicroRNAstatintype 2 diabetes mellitus

Identifiers

PMID32630698
PMCPMC7369709
OpenAlexW3038421643

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.